新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 制药 » AesRx收购Baxter

AesRx收购Baxter

来源:生物谷 2014-07-11 14:49

2014年7月11日讯 /生物谷BIOON/ --作为与NIH合作开展针对镰刀状细胞贫血新药开发的先锋企业,总部位于Newton的AesRx近期收购了Baxter国际,并开始向产业链的上游进军。

AesRx的明星产品是Aes-103,一种口服小分子药物,被设计出来拮抗镰刀状细胞贫血症的影响,希望能够减缓诸如血管阻塞,疼痛,重度贫血和疲劳等症状。

回溯到2010年,Francis Collins执掌的NIH将AesRx作为临床研究伙伴的范例,并寄希望于这样的合作伙伴为病人提供最前沿的医疗进展, 并寻找新的治疗方法。而现在AesRx正在成为NIH用以针对大型药企可以接管并执行末期开发投资的新药研发进展的范例公司。

而镰刀状细胞贫血症的开发证实了该合作模式的可行性。(生物谷Bioon.com)

详细英文报道:

Having played a pioneering role collaborating with the NIH on a new drug for sickle cell disease, Newton, MA-based AesRx has moved up the food chain after completing a buyout deal with Baxter International ($BAX).

The star of the pipeline at AesRx is Aes-103, an oral small molecule therapy that is designed to blunt the impact of the disease, hopefully reducing symptoms like vaso-occlusive crisis, pain, severe anemia and fatigue. The little biotech was an early winner with the NIH's National Center for Advancing Translational Sciences through its program for Therapeutics for Rare and Neglected Diseases, with NIH researchers undertaking much of the development work in Bethesda, MD.

Back in 2010 AesRx was used as an example of the kind of clinical development collaboration that the NIH under Francis Collins wanted to replicate in the hunt for new therapies that could provide some cutting-edge advances for patients. And now it's being used as an example of how the NIH can help advance new drugs to the point bigger players can take over and fund late-stage development.

AesRx also has a Phase II program underway for a gel formulation of Lotrimin (clotrimazole). The anti-inflammatory Aes-210 is being studied for pouchitis, a common complication of ileal pouch surgery. The NIH's assistance on the sickle cell program goes all the way back to preclinical work. And it hopes to use the AesRx example as a model for more such tie-ups with biotechs.

Baxter did not specify how much it paid for the company, either in the upfront or the milestones for successful completion of the work.

''Sickle cell disease was the first disease to ever have its molecular cause discovered, and now a potential treatment based on that discovery has at last been developed,'' said NCATS Director Dr. Christopher Austin in a statement. ''This success validates the NCATS model, which is based on a novel collaborative approach that de-risks intervention development programs to enable private-sector investment. We look forward to applying this model to the thousands of rare diseases that are currently untreatable, so that we realize the NCATS mission of getting more treatments to more patients more quickly.''

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!



相关标签

最新会议 培训班 期刊库